Updates on thrombotic events associated with multiple myeloma

Area of Science:

• Hematology
• Oncology
• Thrombosis Research

Background:

• Venous thromboembolism (VTE) remains a significant risk for Multiple Myeloma (MM) patients, even with current thromboprophylaxis guidelines.
• There is a critical need for improved risk stratification tools and optimized VTE prevention strategies in MM.
• Recent data since 2015 have not yielded breakthrough advancements, highlighting the need for updated approaches.

Purpose of the Study:

• To review recent data on the application and effectiveness of the IMWG 2014 thromboprophylaxis guidelines in MM patients.
• To present new findings on coagulation biomarkers associated with increased VTE risk in MM.
• To discuss advancements in clinical scores for risk stratification and the role of direct oral anticoagulants (DOACs) in VTE prevention for MM.

Main Methods:

• Literature review focusing on studies published since 2015 concerning VTE in MM.
• Analysis of data evaluating the effectiveness of existing guidelines and the application of new biomarkers.
• Discussion of recent clinical scores and emerging evidence on DOACs for thrombosis prevention.

Main Results:

• The review covers the application of IMWG 2014 guidelines and identifies a lack of breakthrough data.
• New potential biomarkers for coagulation and VTE risk in MM patients are presented.
• Recent developments in clinical risk stratification scores and the use of DOACs are discussed.

Conclusions:

• An integrated Risk Assessment Model combining clinical factors and biomarkers is needed for sensitive VTE risk stratification in MM.
• Direct oral anticoagulants (DOACs) are anticipated to play a key role in future VTE prevention strategies for MM patients.
• Ongoing clinical trials are crucial for validating new approaches and guiding management of VTE prevention in MM.